SCHEMBL1028449

SCHEMBL1028449

Clc1cc(N2CCOCC2)nc(Nc2cccnc2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.53
RAF1 P04049 1/20 0.49
BRAF P15056 1/20 0.49
MAPT P10636 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
AKT1 P31749 1/20 0.48
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
PIK3CA P42336 5/20 0.47
KMT2A Q03164 2/20 0.46
SMG1 Q96Q15 3/20 0.46
CDK1 P06493 1/20 0.46
CDK2 P24941 1/20 0.46
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
MTOR P42345 1/20 0.44
JAK3 P52333 1/20 0.44
NTRK2 Q16620 1/20 0.44
CAMK2A Q9UQM7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1028791 0.89 PIK3CA (0.49) RAF1BRAFMAPTCYP1A2CYP2D6
SCHEMBL21313535 0.86 MAPT (0.52) RAF1BRAFMAPTCYP1A2CYP2D6
SCHEMBL3558618 0.82 PIK3CA (0.66) RAF1BRAFCYP1A2CYP2D6HTT
SCHEMBL28085087 0.82 MAPT (0.63) RAF1BRAFMAPTCYP1A2CYP2D6
SCHEMBL26604082 0.82 KMT2A (0.68) RAF1BRAFMAPTCYP1A2CYP2D6
SCHEMBL23321223 0.80 LMNA (0.64) RAF1BRAFMAPTCYP1A2CYP2D6
SCHEMBL26604115 0.80 RAF1 (0.54) RAF1BRAFMAPTCYP1A2CYP2D6
SCHEMBL28057244 0.80 MAPT (0.51) RAF1BRAFMAPTCYP1A2CYP2D6
SCHEMBL1029556 0.80 PIK3CA (0.67) RAF1BRAFHTTPIK3CAPIK3CB
SCHEMBL1028948 0.80 SMN1; SMN2 (0.61) RAF1BRAFMAPTLMNAPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2150546-B1 PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE HOFFMANN LA ROCHE (CH) 2011-01-19 EP disclosed
US-20100130496-A1 PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE F. HOFFMANN-LA ROCHE AG (CH) 2010-05-27 US disclosed
EP-2150546-A2 PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE F. Hoffmann-Roche AG (CH) 2010-02-10 EP disclosed
WO-2008125839-A2 PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE PIRAMED LIMITED (GB) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130496-A1 PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE PIK3CA, PIP5K1B, PIK3CD CHEK1 98/4885RAF1 241/4885BRAF 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.